CVS Health (CVS) is back in focus after reaffirming its earnings guidance and outlining plans to improve Aetna margins, as investors digest a higher than expected 2027 Medicare Advantage payment update and easing regulatory questions around insulin pricing.

The reaffirmed earnings outlook and support for Aetna margins have arrived alongside a 30 day share price return of 11.7% and a 1 year total shareholder return of 26.1%. This suggests recent momentum building on stronger sentiment after regulatory and guidance updates.

If this kind of earnings driven move has your attention, it could be a good moment to scan for other healthcare names using AI as a growth lever via our 33 healthcare AI stocks

With CVS Health now trading at $82.09, a 12 month return of 26.1% and a reported intrinsic discount of about 71%, investors face a clear tension to weigh: is this still mispriced value, or has the rebound already captured future growth potential?

Most Popular Narrative: 21.1% Undervalued

According to a widely followed narrative on CVS Health, the fair value sits at $104.01 compared with the recent $82.09 share price, which frames a sizeable valuation gap for investors to assess.

Regardless of these risks in the near term, the present valuation for CVS indicates that the stock is undervalued by the street. At a P/E ratio of 10x, significantly lower than the sector average, CVS prices in at a 71% discount to its peers and points to some significant upside should it be able to execute on its turnaround strategy.

Curious what sits behind that valuation call. The narrative leans heavily on future earnings power, revenue resilience, and margin repair. The exact mix of growth, profitability and discount rate assumptions is what really drives that $104.01 figure.

Result: Fair Value of $104.01 (UNDERVALUED)

However, investors still need to watch for higher medical costs affecting Aetna margins and any regulatory shifts on Medicare or Medicaid that could compress future profitability assumptions.

Another View: Earnings Multiple Sends a Different Signal

While the narrative points to a fair value of $104.01 and a 71% discount, the current P/E of 59.5x versus a fair ratio of 37.3x and a peer average of 17.3x paints a very different picture. If the market moves closer to that fair ratio, does that suggest potential upside or valuation risk?

Next Steps

With mixed signals on valuation and sentiment in mind, this is a good time to look through the numbers yourself and decide how you feel about CVS Health's balance of opportunity and risk, then weigh up the 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If CVS Health has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to quickly surface fresh stock ideas that fit your style.

• Spot potential value opportunities early by scanning companies that screen as 51 high quality undervalued stocks before they attract wider attention.
• Strengthen your watchlist with businesses highlighted in the solid balance sheet and fundamentals stocks screener (44 results) that may handle tough conditions better than weaker peers.
• Hunt for potential standouts using the screener containing 25 high quality undiscovered gems so you are not only looking where everyone else already is.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.